Searchable abstracts of presentations at key conferences in endocrinology

ea0019p262 | Pituitary | SFEBES2009

Improvements in insulin sensitivity outweigh a decline in pancreatic beta-cell function in newly diagnosed acromegalic subjects treated with primary medical (Somatuline Autogel®) therapy

Gayton E , Annamalai A , Webb A , O'Toole S , Ariyaratnam S , Semple R , Simpson H , Gurnell M

Background: Insulin resistance (IR) commonly manifests in acromegaly leading to impaired glucose tolerance (IGT) and diabetes mellitus (DM). Studies have shown that ‘control’ of growth hormone (GH) and insulin-like growth factor 1 (IGF1) hypersecretion typically ameliorates glucose homeostasis. However, suppression of beta-cell function by somatostatin analogues may potentially attenuate glycaemic benefits of reduced IR. Effects on insulin’s other pleiotropic ef...

ea0019p241 | Pituitary | SFEBES2009

The acromegalic cardiovascular and respiratory outcomes with primary analogue therapy (A.C.R.O.P.A.T.) trial

Webb A , Gayton E , Annamalai A , Pilsworth S , Wallace S , Khan S , O'Toole S , Ariyaratnam S , Maki-Petaja K , Scoffings D , Antoun N , Wilkinson I , Dutka D , Shneerson J , Simpson H , Gurnell M

Seventeen newly-diagnosed acromegalic patients (8 female, 9 male: mean age 55 year, range 26–73 year) were recruited to the A.C.R.O.P.A.T. trial. Patients were assessed prior to, and following, 6 months of treatment with Somatuline Autogel® (SA).Growth hormone (GH) & insulin-like growth factor 1 (IGF1): Following treatment, GH and IGF1 levels fell significantly in all but one subject: median GH change −17.23 mU/l (interquar...